← Back to all trials
Suspended
NCT05948540
Department of Defense PTSD Adaptive Platform Trial - Intervention C - Daridorexant
Conditions: Post Traumatic Stress Disorder
Sex: All
Ages: 18 Years – 65 Years
Healthy volunteers: Yes
Phase: PHASE2
Enrollment: 200
Sponsor: Global Coalition for Adaptive Research
Location: Homestead Associates in Research, Inc. Miami Florida
Summary
This is a Phase 2 randomized, double-blinded, placebo-controlled study that will evaluate multiple potential pharmacotherapeutic interventions for PTSD utilizing an adaptive platform trial design.
Intervention C - Daridorexant will assess the safety and efficacy of daridorexant in participants with PTSD.
Please see NCT05422612 for information on the S-21-02 Master Protocol.
Eligibility Criteria
Inclusion Criteria:
No additional inclusion criteria beyond the inclusion criteria specified in the Master Protocol (NCT05422612).
Exclusion Criteria:
The following exclusion criteria are in addition to the exclusion criteria specified in the Master Protocol (NCT05422612).
1. History of narcolepsy.
2. History of any treatment with daridorexant.
Source: ClinicalTrials.gov (NCT05948540). StuddyBuddy aggregates publicly available trial information.
